Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy.
Since the introduction of highly active antiretroviral therapy (HAART), the frequency of opportunistic disorders (ODs) of the gastrointestinal (GI) tract in human immunodeficiency virus (HIV)-infected patients has fallen dramatically. We have found, however, that despite the use of HAART, HIV-infected patients can still present with GI ODs. To evaluate the prevalence of GI ODs in HIV-infected patients on HAART who were undergoing endoscopic evaluation for GI-related symptoms. From January 1996 through February 2002, all HIV-infected patients undergoing GI endoscopy were prospectively identified; mucosal biopsies were obtained in a standardized fashion and histologic specimens were examined by a single GI pathologist. All the patients on HAART presenting with a GI OD are described. Results showed that 294 patients (88% men; mean age, 36.5 +/- 10 years; median CD4 lymphocyte count, 64 cells/microl; range, 1-884; median viral RNA level, 40,357 copies/ml; range, 0-7,721,715) underwent 401 upper and/or lower endoscopies during the study period. The use of HAART increased from 10% in early 1996 to 85% in 2002. Nevertheless we found that 27 patients (9%) presented with a GI OD despite HAART. Forty percent of the patients with a GI OD were noncompliant with HAART. We conclude that GI ODs can occur despite HAART and normal CD4 counts. The prevalence of GI ODs in HIV-infected patients taking HAART is 9%. The reasons for this are multifactorial and likely include noncompliance with medications, viral resistance to the drugs, and decreased drug bioavailability. Although the use of HAART has led to a decreased incidence of GI ODs in AIDS, the gastroenterologist evaluating these patients should not discard the possibility that the GI symptoms in HIV-infected patients taking HAART may be secondary to an OD, even when the CD4 count is normal and the viral load is low.
Mönkemüller
Klaus E
KE
Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Klaus.Moenkemueller@medizin.uni-magdeburg.de
Lazenby
Audrey J
AJ
Lee
David H
DH
Loudon
Robert
R
Wilcox
C Mel
CM
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016099:Endoscopy, Gastrointestinal; D005260:Female; D019053:HIV Enteropathy / Q000175:diagnosis / Q000453:epidemiology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D015995:Prevalence; D019562:Viral Load
AIDS. 1997 Nov;11(13):1653-5
9365774
N Engl J Med. 1997 May 22;336(21):1531-2
9157292
Am J Gastroenterol. 2000 Feb;95(2):457-62
10685750
N Engl J Med. 1996 Oct 10;335(15):1081-90
8813038
Ann Intern Med. 1996 Aug 1;125(3):161-72
8686973
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):213-7
10795595
N Engl J Med. 1996 Feb 15;334(7):426-31
8552144
Arch Intern Med. 2001 Sep 10;161(16):1962-8
11525698
Ann Intern Med. 2000 Oct 3;133(7):493-503
11015162
Gastroenterology. 2001 Feb;120(3):607-21
11179239
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
South Med J. 1999 Jul;92(7):677-83
10414476
Ann Intern Med. 2000 Sep 19;133(6):447-54
10975963
Ann Intern Med. 1999 Jul 20;131(2):81-7
10419445
Gastrointest Endosc Clin N Am. 1998 Oct;8(4):889-911
9730938
JAMA. 1998 Jun 24;279(24):1984-91
9643863
Lancet. 1998 Jan 24;351(9098):256-61
9457096